Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C53H90N14O16 |
| Molecular Weight | 1179.3659 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](C)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C)C(=O)N[C@H](C)C(N)=O
InChI
InChIKey=GHHZWRGZMXHMIQ-DZLDEHGNSA-N
InChI=1S/C53H90N14O16/c1-12-26(6)40(64-50(80)37-16-13-19-66(37)52(82)35(22-25(4)5)63-45(75)30(10)58-43(73)27(7)54)53(83)67-20-14-15-36(67)49(79)62-33(21-24(2)3)47(77)61-34(23-39(70)71)48(78)60-32(17-18-38(55)69)46(76)65-41(31(11)68)51(81)59-29(9)44(74)57-28(8)42(56)72/h24-37,40-41,68H,12-23,54H2,1-11H3,(H2,55,69)(H2,56,72)(H,57,74)(H,58,73)(H,59,81)(H,60,78)(H,61,77)(H,62,79)(H,63,75)(H,64,80)(H,65,76)(H,70,71)/t26-,27+,28+,29+,30+,31+,32-,33-,34-,35-,36-,37-,40-,41-/m0/s1
| Molecular Formula | C53H90N14O16 |
| Molecular Weight | 1179.3659 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 20:18:02 GMT 2023
by
admin
on
Sat Dec 16 20:18:02 GMT 2023
|
| Record UNII |
A6KAB92LQ7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
A6KAB92LQ7
Created by
admin on Sat Dec 16 20:18:03 GMT 2023 , Edited by admin on Sat Dec 16 20:18:03 GMT 2023
|
PRIMARY | |||
|
2219362-20-4
Created by
admin on Sat Dec 16 20:18:03 GMT 2023 , Edited by admin on Sat Dec 16 20:18:03 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Binds selectively to ENaC and promotes internalization of the a-, b-, and g-subunits.
Removing ENaC from the membrane with SPX-101 causes a significant decrease in amiloride-sensitive current.
EC50
|
||
|
TARGET->MIMETIC |
Leads to ENAC sustained ENAC down regulation.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
